Scientists probe brain chemistry to unlock thinking problems in schizophrenia
NCT ID NCT07162467
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looks at how a specific brain chemical pathway (tryptophan-kynurenine) relates to thinking and memory problems in people with schizophrenia. Researchers will measure blood levels of these chemicals and assess cognitive function in 200 participants, including healthy volunteers. The goal is to find early markers of cognitive impairment and identify potential targets for future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward new treatments for cognitive problems in schizophrenia and help identify thinking issues earlier.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead directly to new therapies, and results may not apply to all people with schizophrenia.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Anding Hospital
Tianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a video call strengthen families facing schizophrenia?
- Virtual family therapy may tame schizophrenia symptoms — a trial investigates
- Could a Once-Every-Few-Weeks shot replace daily pills for schizophrenia?
- Can a tailored self-management program improve health outcomes for those with serious mental illness?
- PET scans reveal how antipsychotics target key brain receptors in schizophrenia
- Immune clues in schizophrenia: could inflammation subtypes guide treatment?